Literature DB >> 5026380

Relation of hydralazine plasma concentration to dosage and hypotensive action.

R Zacest, J Koch-Weser.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5026380     DOI: 10.1002/cpt1972133420

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  37 in total

Review 1.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

2.  Clinical pharmacokinetics of hydrallazine.

Authors:  T Talseth
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

3.  Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects.

Authors:  P Brunel; J B Lecaillon; T T Guyene; P Imhof; J Ménard
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

Review 4.  Survey of the human acetylator polymorphism in spontaneous disorders.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1984-08       Impact factor: 6.318

5.  Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.

Authors:  K Carr; J A Oates; A S Nies; R L Woosley
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

6.  The lupus syndrome induced by hydralazine: a common complication with low dose treatment.

Authors:  H A Cameron; L E Ramsay
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-18

7.  Acute effects of prizidilol on blood pressure, heart rate, catecholamines, renin and aldosterone in essential hypertension.

Authors:  M G Bianchetti; K Boehringer; P Weidmann; L Link; H Schiffl; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1982-10       Impact factor: 2.953

8.  Studies on hydralazine. II. Elimination rate and steady-state concentration in patients with impaired renal function.

Authors:  T Talseth
Journal:  Eur J Clin Pharmacol       Date:  1976-09-30       Impact factor: 2.953

9.  Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?

Authors:  L E Ramsay; J H Silas; J D Ollerenshaw; G T Tucker; F C Phillips; S Freestone
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Polymorphic acetylation of sulphadimidine in normal and uraemic man.

Authors:  T Talseth; K H Landmark
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.